文献速递认知障碍与痴呆神经肌肉病

阿尔茨海默病及相关障碍诊疗中流体生物标志物的进展

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.
PubMed 文献 · Lancet Neurol · 2026-01-01

本文综述了阿尔茨海默病流体生物标志物的快速发展,指出血液标志物如神经丝轻链和磷酸化tau 217已进入临床实践,并强调需多种标志物捕捉疾病机制复杂性,未来需扩展诊断方法、即时检测和远程采样。

要点

  • 血液标志物如NfL和p-tau217已用于额颞叶痴呆、ALS和AD诊断。
  • 多种流体标志物可反映血管、α-突触核蛋白和TDP-43等病理。
  • 生物标志物有助于捕捉治疗过程中的异质性。

核心结论

  • 流体生物标志物在阿尔茨海默病及相关障碍的诊疗中快速发展并逐步进入临床实践。

主要发现

  • 超灵敏和多重组技术及高特异性抗体的突破推动了流体生物标志物的发展。
  • 血液标志物如神经丝轻链用于额颞叶痴呆和肌萎缩侧索硬化,磷酸化tau 217用于阿尔茨海默病诊断,已进入临床实践。
  • 多种流体标志物可捕捉血管、α-突触核蛋白和TDP-43等病理。
  • 流体标志物可帮助捕捉患者间治疗过程的异质性,可能与共病理或微胶质和星形胶质细胞失调等关键中介有关。
  • 实验模型中关注生物标志物-病理关系可能加速标志物开发并加深对其精确底物的理解。

临床怎么用

  • 血液标志物如磷酸化tau 217可用于阿尔茨海默病诊断,神经丝轻链可用于额颞叶痴呆和肌萎缩侧索硬化。
  • 多种流体标志物联合使用有助于精确诊断和评估导致痴呆的多样病理。
  • 流体标志物可用于捕捉患者治疗过程中的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fluid biomarkers for Alzheimer's disease have advanced rapidly during the past several years driven by breakthroughs including development of ultrasensitive and multiplexing technologies and high specificity antibodies. Blood-based biomarkers, such as neurofilament light for frontotemporal dementia and amyotrophic lateral sclerosis, and phosphorylated tau 217 for the diagnosis of Alzheimer's disease, are now being implemented in clinical practice, which is particularly timely because of the increasing clinical availability of amyloid-targeting treatments in Alzheimer's disease. Multiple fluid biomarkers are needed to capture the complexity of disease mechanisms for precise diagnosis and to measure the diverse pathologies that lead to dementia, such as vascular, α-synuclein, and TDP-43 pathologies. Moreover, fluid biomarkers can aid in capturing heterogeneity in treatment course between patients, probably due to copathologies or key intermediates, including microglia and astrocyte dysregulation. Increased focus on biomarker-pathology relationships in experimental models will likely accelerate biomarker development and further the understanding of their precise substrates. Future clinical implementation of biomarkers to capture the full complexity of pathologies will likely be facilitated by the expansion of diagnostic methods, development of point of care technologies, and remote sampling approaches.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Teunissen CE, Vermunt L, Barthélemy NR, et al. Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders. Lancet Neurol. 2026. PMID: 42716045. doi:10.1016/S1474-4422(26)00246-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。